Brief Summary
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advancedat a late stage, far along solid tumors.
Intervention / Treatment
- Drug: ALTA2618
Inclusion Criteria:
- Histologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of a solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test.
- Unresectable or metastatic disease
- Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapymedication that targets specific molecular features of cancer cells, if applicable) appropriate to tumor type and stage
- Evaluable or measurable disease per RECIST v1.1
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 or 1.
- Adequate organ function.